Moderna (MRNA) Cash & Equivalents (2017 - 2026)

Moderna has reported Cash & Equivalents for 10 years, with the latest figure at $1.7 billion in Q2 2026.

• Cash & Equivalents for Q2 2026 came in at $1.7 billion, up 34.71% year-over-year; the trailing twelve-month figure through Jun 2026 was $1.7 billion (up 34.71% YoY), and the FY2025 annual result was $2.6 billion, up 34.67% from the prior year.
• Cash & Equivalents slipped to $1.7 billion in Q2 2026, from $1.9 billion in the prior quarter.
• Over five years, Cash & Equivalents peaked at $5.0 billion in Q1 2022 and troughed at $1.1 billion in Q3 2025.
• A 5-year average of $2.5 billion and a median of $2.5 billion in 2024 frame the typical range for Cash & Equivalents.
• The widest annual swing landed in 2022, when Cash & Equivalents plunged 53.2%; it then jumped 34.71% in 2026.
• A 5-year view of Cash & Equivalents shows it stood at $3.2 billion in 2022, then retreated by 9.3% to $2.9 billion in 2023, then plunged by 33.71% to $1.9 billion in 2024, then jumped by 34.67% to $2.6 billion in 2025, then slumped by 33.6% to $1.7 billion in 2026.
• Per Business Quant data, the three most recent Cash & Equivalents figures were $1.7 billion in Q2 2026, $1.9 billion in Q1 2026, and $2.6 billion in Q4 2025.